[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623942":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":24,"responsibleParty":41,"collaborators":10,"id":43,"slug":10,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Kyverna Therapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Cohort 1",null,[12],"Drug: KYV-101",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","KYV-101","Autologous fully-human anti-CD19 chimeric antigen receptor T-cell (CD19 CAR T) product.",[9],[20],{"name":5,"role":21,"phone":22,"phoneExt":10,"email":23},"CONTACT","510-925-2484","clinicaltrials@kyvernatx.com",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"University of Colorado, Denver","RECRUITING","Denver","Colorado","80045","United States",{"type":33,"coordinates":34},"Point",[35,36],-104.9847,39.73915,{"lat":36,"lon":35},[39],{"name":40,"role":21,"phone":10,"phoneExt":10,"email":10},"Study Coordinator",{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100623942",false,"NCT07403188","A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101","KYSA-4","Inclusion Criteria:\n\n* Provided informed consent for the LTFU study\n* Received at least 1 infusion of KYV-101 as part of a previous KYV-101 parent treatment protocol\n\nExclusion Criteria:\n\n* Not applicable","ALL","18 Years",{"count":52,"type":53},70,"ESTIMATED","OBSERVATIONAL","The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product).\n\nThis LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).",[57,58,59,60,61,62,63],"Refractory Lupus Nephritis","Myasthaenia Gravis","Stiff Person Syndrome","Rheumatoid Arthritis (RA)","Multiple Sclerosis","Dermatomyositis","Systemic Sclerosis (SSc)","2026-02-03",{"date":66,"type":67},"2026-02-11","ACTUAL",{"date":69,"type":67},"2025-11-24",{"date":71,"type":53},"2041-01",{"name":5,"class":6},1]